AAIC 2025 Abstract

Absolute risk of cognitive impairment by AD amyloid stages

Study in peopleBiomarkers

Abstract

Background: Despite advances in Alzheimer’s disease (AD) research, limited information exists regarding the absolute risk of mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals with abnormal AD biomarkers, particularly when accounting for competing risks of death.

The paper

Mayo Clinic

AAIC 2025 Abstract, 23 Dec 2025, CC BY

Presented at AAIC 2025

doi.org/10.1002/alz70862_109822